A Phase 1 clinical trial to test the safety, preliminary effects of increasing doses of AZD7648 alone and in combination with other anti-cancer agents in patients with advanced cancers..

Registry ID

EUCTR2018-003688-73

Source registry

EUCTR

Status

GB - no longer in EU/EEA

Phase

PHASE2

Sponsor

AstraZeneca AB

Start date

2019-04-05

Last update

2026-08-16

Conditions

• Advanced Malignancies

Summary

_Evaluate, efficacy, safety and tolerability of IMP _To investigate the safety and tolerability of AZD7648 when given orally to patients with advanced malignancies, as monotherapy and in combination with anticancer agents, and to define the doses and schedules for further clinical evaluation.

Locations

• , , UK

Related clinical trials

• Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
• Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
• An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
• A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
• An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
• BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

View on source registry